Full-Time
Confirmed live in the last 24 hours
Develops cortisol modulators for medical conditions
$154.1k - $181.3k/yr
Senior, Expert
San Carlos, CA, USA
This is a hybrid role typically requiring on-site presence 3 days per week.
Get referrals →
You have ways to get a Corcept Therapeutics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is an FDA-approved medication for Cushing's syndrome, a condition caused by excessive cortisol. Corcept has created over 1,000 cortisol modulators through extensive research and development, aiming to expand their treatment options for patients with cortisol-related disorders. Unlike many competitors, Corcept emphasizes both drug development and patient education, providing resources to improve understanding and care for these conditions. The company's goal is to enhance patient outcomes by offering effective treatments and educational support.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
CORCEPT to present late-breaking data from pivotal Phase 3 ROSELLA trial of Relacorilant in platinum-resistant Ovarian Cancer at ASCO 2025.
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.
Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.